SGLT2 Inhibitors and GLP-1 Drugs Reduce Gout Risk in Danish Population Study
A Danish population-based study found that SGLT2 inhibitors are associated with reduced gout risk compared to other diabetes medications, with GLP-1 drugs also showing potential benefit.
Quick Facts
What This Study Found
SGLT2 inhibitors associated with reduced gout risk compared to other antidiabetic medications in a Danish population-based cohort. GLP-1 peptides also showed potential gout risk reduction.
Key Numbers
N=11,047 pairs; 42,201 person-years; HR 0.58 (0.44-0.75); IRD -3.0; SR 0.63 (0.47-0.84); 4.1 vs 7.0/1000 PY
How They Did This
Danish population-based cohort study. SGLT2 inhibitor and GLP-1 RA use compared to other antidiabetic medications for gout incidence.
Why This Research Matters
Gout affects millions of diabetes patients and causes debilitating pain. Drugs that control blood sugar AND reduce gout risk provide dual benefits, informing medication choice for patients with both conditions.
The Bigger Picture
SGLT2 inhibitors and GLP-1 drugs continue accumulating benefits beyond glucose control — cardiovascular, renal, and now potentially gout protection. This multi-benefit profile strengthens their position as preferred diabetes medications.
What This Study Doesn't Tell Us
Observational population study — cannot prove causation. Confounding by indication possible. GLP-1 gout evidence less robust than SGLT2i. Danish population may not generalize to other ethnicities.
Questions This Raises
- ?Would SGLT2 inhibitors prevent gout in non-diabetic patients with hyperuricemia?
- ?Is the gout benefit stronger with specific SGLT2i drugs?
- ?Does the GLP-1 gout reduction persist in prospective studies?
Trust & Context
- Key Stat:
- Diabetes drugs prevent gout SGLT2 inhibitors reduce gout risk by increasing kidney uric acid excretion — a bonus benefit for diabetes patients who commonly suffer from gout
- Evidence Grade:
- Moderate evidence: large population-based cohort study with real-world data, but observational design limits causal conclusions.
- Study Age:
- Published 2021. SGLT2i effects on uric acid and gout continue to be confirmed.
- Original Title:
- Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis.
- Published In:
- Pharmacoepidemiology and drug safety, 30(10), 1391-1395 (2021)
- Authors:
- Lund, Lars Christian(2), Højlund, Mikkel, Henriksen, Daniel Pilsgaard, Hallas, Jesper, Kristensen, Kasper Bruun
- Database ID:
- RPEP-05569
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can diabetes drugs prevent gout?
This Danish study suggests SGLT2 inhibitors reduce gout risk, likely by helping the kidneys excrete more uric acid. GLP-1 drugs also showed potential benefit. If you have diabetes and gout, these drug classes may address both conditions.
How do SGLT2 inhibitors reduce uric acid?
SGLT2 inhibitors work by making the kidneys excrete excess glucose in urine. This process also increases uric acid excretion, lowering blood uric acid levels — the root cause of gout.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05569APA
Lund, Lars Christian; Højlund, Mikkel; Henriksen, Daniel Pilsgaard; Hallas, Jesper; Kristensen, Kasper Bruun. (2021). Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis.. Pharmacoepidemiology and drug safety, 30(10), 1391-1395. https://doi.org/10.1002/pds.5252
MLA
Lund, Lars Christian, et al. "Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis.." Pharmacoepidemiology and drug safety, 2021. https://doi.org/10.1002/pds.5252
RethinkPeptides
RethinkPeptides Research Database. "Sodium-glucose cotransporter-2 inhibitors and the risk of go..." RPEP-05569. Retrieved from https://rethinkpeptides.com/research/lund-2021-sodiumglucose-cotransporter2-inhibitors-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.